PureTech Health plc (NASDAQ:PRTC) shares saw unusually-strong trading volume on Wednesday . Approximately 1,218 shares changed hands during trading, a decline of 37% from the previous session’s volume of 1,946 shares.The stock last traded at $48.13 and had previously closed at $47.70.
Several research analysts have commented on the stock. SVB Leerink boosted their price target on shares of PureTech Health from $74.00 to $76.00 and gave the stock an “outperform” rating in a report on Wednesday, August 25th. Zacks Investment Research cut shares of PureTech Health from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Piper Sandler lowered their price target on shares of PureTech Health from $76.00 to $72.00 and set an “overweight” rating for the company in a report on Wednesday, August 25th.
The company has a market cap of $1.38 billion and a PE ratio of 2,406.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.29 and a current ratio of 2.29. The stock’s 50-day simple moving average is $47.67 and its 200 day simple moving average is $52.68.
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions.
Featured Story: What Are Cryptocurrencies?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.